Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Identifying Sustainable Pathways Toward Oligonucleotide Therapeutics | Contract Pharma

What are you searching for?

Sign in
White Papers / Tech Papers

Identifying Sustainable Pathways Toward Oligonucleotide Therapeutics

After nearly 50 years of research and development, oligonucleotide therapeutics are starting to make their mark on the pharmaceutical scene.

Released By Ajinomoto Bio-Pharma Services

After nearly 50 years of research and development, oligonucleotide therapeutics are starting to make their mark on the pharmaceutical scene. Over the next several years, the market is poised to grow significantly, with 16 oligonucleotide drugs approved in Japan in 2022.

As interest in therapeutic oligonucleotides accelerates, manufacturers and researchers are working to identify and develop processes that address the significant environmental burdens of oligonucleotide manufacturing while saving resources and improving scalability.

FILL OUT FORM TO DOWNLOAD THE WHITE PAPER >>>>>

Download White Papers / Tech Papers Now

Download White Papers / Tech Papers Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters